Neurotensin(8-13)(Synonyms: 神经降压素(8-13)) | Cytiva思拓凡-Whatman滤纸滤膜滤器

Neurotensin(8-13) (Synonyms: 神经降压素(8-13)) 纯度: ≥98.0%

Neurotensin (8-13) 是神经降压素的活性片段，Neurotensin (8-13) 降低细胞表面NT1受体 (NTR1) 密度。

Neurotensin(8-13) Chemical Structure

CAS No. : 60482-95-3

规格	价格	是否有货
1 mg	￥600	In-stock
5 mg	￥1200	In-stock
10 mg	￥2100	In-stock
25 mg	￥4400	In-stock
50 mg		询价
100 mg		询价

* Please select Quantity before adding items.

Neurotensin(8-13) 相关产品

•相关化合物库:

Bioactive Compound Library Plus
Peptidomimetic Library
Peptide Library

生物活性

Neurotensin (8-13) is an active fragment of Neurotensin. Neurotensin(8-13) results in a decrease in cell-surface NT1 receptors (NTR1) density.

IC₅₀ & Target

NTR1^[1]

体外研究
(In Vitro)

Receptor internalization induced by Neurotensin(8-13) results in a decrease in cell-surface NT1 receptors (NTR1) density. The receptor downregulation in response to high extracellular concentrations of the peptide has been described for Neurotensin (NT) in HT-29 cells and in rat primary cultured neurons. Reappearance of the receptors on the cell surface is also different^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

816.99

Formula

C₃₈H₆₄N₁₂O₈

CAS 号

60482-95-3

Sequence

Arg-Arg-Pro-Tyr-Ile-Leu

Sequence Shortening

RRPYIL

中文名称

神经降压素(8-13)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Protect from light

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据

In Vitro:

H₂O : 50 mg/mL (61.20 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.2240 mL	6.1200 mL	12.2401 mL
5 mM	0.2448 mL	1.2240 mL	2.4480 mL
10 mM	0.1224 mL	0.6120 mL	1.2240 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

参考文献

[1]. García-Garayoa E, et al. Preclinical evaluation of a new, stabilized neurotensin(8–13) pseudopeptide radiolabeled with (99m)tc. J Nucl Med. 2002 Mar;43(3):374-83.

Kinase Assay ^[1]	Binding assays are performed on whole HT-29 cells at confluence. A day before the assay, cells (10⁶ cells/0.4 mL, equivalent to 0.3 mg protein) are placed in 48-well plates. A special binding buffer that includes protease inhibitors (50 mM HEPES, 125 mM NaCl, 7.5 mM KCl, 5.5 mM MgCl₂, 1 mM EGTA, 5 g/L bovine serum albumin, 2 mg/L chymostatin, 100 mg/L soybean trypsin inhibitor, 50 mg/L bacitracin, pH 7.4) is used for the experiments. In inhibition studies, cells are incubated for 1 h at 37°C in triplicate with 25,000 cpm of ¹²⁵I-NT and variable concentrations (0.001-3,000 nM) of unlabeled NT(8-13), unlabeled NT-VIII, or NT-VIII labeled with ^natRe (final volume of 0.2 mL per well). The cells are then washed twice with cold binding buffer and afterward are solubilized with 1N NaOH at 37°C (0.4 mL per well). The activity is determined in a γ-counter. In saturation studies, cells are incubated in triplicate with increasing concentrations (0.1-10 nM) of ^99mTc(CO)3NT-VIII for 1 h at 37°C (final volume, 0.2 mL per well). The concentrations of total technetium (^99+99mTc) are equivalent to 0.2-20 MBq ^99mTc activity per well. After 2 washings with the same binding buffer as before, the cells are then solubilized with 1N NaOH at 37°C (0.4 mL per well). The bound radioactivity is measured in the γ-counter. Nonspecific binding is determined with 1 μM unlabeled NT(8-13)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. García-Garayoa E, et al. Preclinical evaluation of a new, stabilized neurotensin(8–13) pseudopeptide radiolabeled with (99m)tc. J Nucl Med. 2002 Mar;43(3):374-83.

Kinase Assay
^[1]

Binding assays are performed on whole HT-29 cells at confluence. A day before the assay, cells (10⁶ cells/0.4 mL, equivalent to 0.3 mg protein) are placed in 48-well plates. A special binding buffer that includes protease inhibitors (50 mM HEPES, 125 mM NaCl, 7.5 mM KCl, 5.5 mM MgCl₂, 1 mM EGTA, 5 g/L bovine serum albumin, 2 mg/L chymostatin, 100 mg/L soybean trypsin inhibitor, 50 mg/L bacitracin, pH 7.4) is used for the experiments. In inhibition studies, cells are incubated for 1 h at 37°C in triplicate with 25,000 cpm of ¹²⁵I-NT and variable concentrations (0.001-3,000 nM) of unlabeled NT(8-13), unlabeled NT-VIII, or NT-VIII labeled with ^natRe (final volume of 0.2 mL per well). The cells are then washed twice with cold binding buffer and afterward are solubilized with 1N NaOH at 37°C (0.4 mL per well). The activity is determined in a γ-counter. In saturation studies, cells are incubated in triplicate with increasing concentrations (0.1-10 nM) of ^99mTc(CO)3NT-VIII for 1 h at 37°C (final volume, 0.2 mL per well). The concentrations of total technetium (^99+99mTc) are equivalent to 0.2-20 MBq ^99mTc activity per well. After 2 washings with the same binding buffer as before, the cells are then solubilized with 1N NaOH at 37°C (0.4 mL per well). The bound radioactivity is measured in the γ-counter. Nonspecific binding is determined with 1 μM unlabeled NT(8-13)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. García-Garayoa E, et al. Preclinical evaluation of a new, stabilized neurotensin(8–13) pseudopeptide radiolabeled with (99m)tc. J Nucl Med. 2002 Mar;43(3):374-83.

[1]. García-Garayoa E, et al. Preclinical evaluation of a new, stabilized neurotensin(8–13) pseudopeptide radiolabeled with (99m)tc. J Nucl Med. 2002 Mar;43(3):374-83.